Holen Sie sich die Stockscreener-App
3.70
0.27%
-0.010
Vorhandelsmarkt:
3.70
Schlusskurs vom Vortag:
$3.71
Offen:
$3.66
24-Stunden-Volumen:
10,055
Relative Volume:
0.44
Marktkapitalisierung:
$110.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.77M
KGV:
-24.88
EPS:
-0.1487
Netto-Cashflow:
$-1.46M
1W Leistung:
+2.78%
1M Leistung:
+10.45%
6M Leistung:
-14.35%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.66
$3.8776
1-Wochen-Bereich:
$3.40
$3.90
52-Wochen-Spanne:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Firmenname
Turn Therapeutics Inc
Sektor
Branche
Telefon
(818) 564-4011
Adresse
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.70 | 110.22M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-29 | Eingeleitet | D. Boral Capital | Buy |
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
Why Turn Therapeutics (TTRX) earnings always move the needle |Shared Buy Zones - Newser
Is Turn Therapeutics (TTRX) stock changing direction |Subscription Growth - Newser
TTRX Price Today: Turn Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Turn Therapeutics (NASDAQ:TTRX) Trading 6% HigherShould You Buy? - MarketBeat
TTRX (Turn Therapeutics) CEO set to share wound care pipeline outlook alongside its upcoming quarterly earnings report.Analyst Recommended Stocks - Newser
Is Turn Therapeutics (TTRX) Stock a future winner | Price at $3.38, Down 3.70%Wall Street Picks - Newser
What are bearish arguments for Turn Therapeutics (TTRX) Stock | Price at $3.43, Down 2.00%Investment Picks - Newser
Bradley Burnam holds 52.76% of Turn Therapeutics (NASDAQ: TTRX) common stock - Stock Titan
Is Turn Therapeutics (TTRX) Stock Overvalued Now | Price at $3.36, Up 0.30%Top Trending Breakouts - Newser
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World
Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today
Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M - Stock Titan
Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares - Stock Titan
Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike - Stock Titan
80K options granted at $3.12 to Turn Therapeutics (TTRX) - Stock Titan
TTRX Stock Analysis: Turn Therapeutics Inc at 3.35 USD post 7.54 percent daily gain - Cổng thông tin điện tử tỉnh Tây Ninh
[EFFECT] Turn Therapeutics Inc. SEC Filing - Stock Titan
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - BioSpace
Turn Therapeutics (TTRX) registers up to 7,000,000 shares for GEM resale - Stock Titan
Turn Therapeutics (TTRX) registers 17.87M shares for resale by stockholders - Stock Titan
Turn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Turn Therapeutics (TTRX) details eczema drug plans and going-concern risk - Stock Titan
Turn Therapeutics (NASDAQ: TTRX) widens 2025 loss but secures $25M growth capital - Stock Titan
Turn Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TTRX SEC FilingsTurn Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat
TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Ana - GuruFocus
Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - MarketScreener
Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka
Turn Therapeutics Inc. (TTRX) Stock forecasts - Yahoo Finance UK
Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX - MarketBeat
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga España
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - MarketBeat
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Finanzdaten der Turn Therapeutics Inc-Aktie (TTRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Turn Therapeutics Inc-Aktie (TTRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):